Bevacizumab with Temozolomide and Radiation for Newly Diagnosed Glioblastoma
This study is looking at a new way to treat newly diagnosed glioblastoma (a type of brain cancer). It compares giving a drug called bevacizumab (Avastin) directly into the brain's arteries (Superselective Intraarterial Cerebral Infusion or SIACI) along with standard treatment (temozolomide and radiation) to just receiving temozolomide and radiation alone. Researchers want to see if adding bevacizumab this way helps people live longer. You might be able to join if you are 18 or older and have a confirmed diagnosis of glioblastoma. The study plans to enroll 432 people, but its current status is unclear.
- Study design
- This is an interventional study with an unclear phase. It compares two treatment approaches in a planned enrollment of 432 participants.
- What's involved
- If in the treatment group, you would receive bevacizumab infusions every three months for a total of three infusions, in addition to daily oral temozolomide and radiation for 42 days, followed by rest and maintenance cycles. If in the control group, you would receive daily oral temozolomide and radiation for 42 days, followed by rest and maintenance cycles.
- Compensation
- Not stated in the trial record.
- Follow-up
- Overall survival will be measured at 62 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- John Boockvar, MD · PRINCIPAL_INVESTIGATOR · Feinstein Institute for Medical Research/Lenox Hill Hospital
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Overall survival (OS)62 months
The primary end point will be overall survival (OS). Overall survival is defined as the time from randomization until death due to any cause. Participants who are still alive at the time of analysis will be censored at their last known alive date.